The tumor model used here, MC38 colon adenocarcinoma, has been shown to have a high mutational load [46] and to express PDL-1 on tumor cells and the tumor microenvironment [47] and has therefore extensively been used as a target model for immunotherapy involving PD-1 or PD-L1 blockade. The gene discussed is CD274; the disease is colon adenocarcinoma.